AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7361797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 g four times daily)
Number of subjects: 20
Study 7361797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31645648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pLSC6 group (n=97)
Number of subjects: 163
Study 31645648 — intervention group
Group type: COMPARATOR
Intervention: High-pLSC6 group (n=66)
Number of subjects: 163
Study 30550828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 280 mg plus class 3 topical corticosteroids (TCS)
Number of subjects: 113
Study 30550828 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus class 3 topical corticosteroids (TCS)
Number of subjects: 113
Study 30550828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab plus TCS
Number of subjects: 113
Study 30550828 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus TCS
Number of subjects: 113
Study 27576298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal standard nursing program (MSNP) plus routine nursing care
Number of subjects: 12
Study 27576298 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 12
Study 23336594 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO 2 g plus folic acid 200 mg every day
Number of subjects: 50
Study 23336594 — intervention group
Group type: COMPARATOR
Intervention: Folic acid 200 mg every day
Number of subjects: 50
Study 21070547 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-angle glaucoma patients
Number of subjects: 54
Study 21070547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 20012809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (tailored print communication and brief telephone-based motivational interviewing)
Number of subjects: 0
Study 20012809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print communication (TPC)
Number of subjects: 0
Study 20012809 — intervention group
Group type: COMPARATOR
Intervention: None of the interventions
Number of subjects: 0
Study 17347063 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL 5 mg
Number of subjects: 128
Study 17347063 — intervention group
Group type: COMPARATOR
Intervention: ALN 70 mg
Number of subjects: 128
Study 14748812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (n = 28)
Number of subjects: 49
Study 14748812 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (n = 21)
Number of subjects: 49
Study 11785453 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilaraemia detection using thick drop technique and nucleopore filtration technique.
Number of subjects: 4646
Study 11785453 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examinations for disease manifestations.
Number of subjects: 4646
Study 11785453 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of occult filarial manifestations.
Number of subjects: 4646
Study 9301399 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural buprenorphine
Number of subjects: 2
Study 9301399 — intervention group
Group type: COMPARATOR
Intervention: Continuous extradural bupivacaine
Number of subjects: 2
Study 8373713 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 0
Study 8373713 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 0
Study 8373713 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 0
Study 8373713 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam 10 mg
Number of subjects: 0
Study 8373713 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (5 and 10 mg) after seven nightly doses
Number of subjects: 0
Study 8373713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly administration of zolpidem
Number of subjects: 0
Study 3763945 — intervention group
Group type: EXPERIMENTAL
Intervention: Meteneprost potassium (a PGE2 analogue)
Number of subjects: 30
Study 29865169 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole nut consumption
Number of subjects: 50
Study 29865169 — intervention group
Group type: COMPARATOR
Intervention: Nut butter consumption
Number of subjects: 50
Study 29865169 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts with yogurt
Number of subjects: 50
Study 29865169 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 50
Study 28027368 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention (6 sessions of individual problem-solving therapy delivered by trained, supervised lay health workers plus an optional 6-session peer support program)
Number of subjects: 573
Study 28027368 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention
Number of subjects: 573
Study 28027368 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 573
Study 24534735 — intervention group
Group type: EXPERIMENTAL
Intervention: £1000 incentive
Number of subjects: 275
Study 24534735 — intervention group
Group type: EXPERIMENTAL
Intervention: £25 incentive
Number of subjects: 275
Study 24534735 — intervention group
Group type: EXPERIMENTAL
Intervention: £1000 incentive without cognitive load
Number of subjects: 275
Study 24534735 — intervention group
Group type: EXPERIMENTAL
Intervention: £25 incentive without cognitive load
Number of subjects: 275
Study 24534735 — intervention group
Group type: EXPERIMENTAL
Intervention: £1000 incentive under cognitive load
Number of subjects: 275
Study 24534735 — intervention group
Group type: EXPERIMENTAL
Intervention: £25 incentive under cognitive load
Number of subjects: 275
Study 23134686 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telemarketing approach to promote healthy eating, physical activity, and weight loss
Number of subjects: 0
Study 23134686 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive support services offered via telemarketing
Number of subjects: 0
Study 19631948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20mg
Number of subjects: 94
Study 19631948 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150mg
Number of subjects: 94
Study 19631948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 19631948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20mg and Venlafaxine 150mg
Number of subjects: 94
Study 18586659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 7.5 mg/kg
Number of subjects: 79
Study 18586659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 15 mg/kg
Number of subjects: 79
Study 16028436 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity programme (30 min of brisk walking and a daily 11-min home-based programme)
Number of subjects: 43
Study 12503699 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled 10 min before mannitol
Number of subjects: 20
Study 12503699 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled 5 min after mannitol
Number of subjects: 20
Study 12503699 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline inhaled 10 min before the control for mannitol
Number of subjects: 20
Study 10519734 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (mean dose 28.6 mg/day)
Number of subjects: 43
Study 10519734 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (mean dose 19.3 g/day)
Number of subjects: 43
Study 7734901 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20 mg/kg
Number of subjects: 33
Study 7734901 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline 5 mg/kg
Number of subjects: 33
Study 2007101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block with 2% lidocaine plus epinephrine (Group A)
Number of subjects: 45
Study 2007101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block with 2% lidocaine plus ornipressin (Group B)
Number of subjects: 45
Study 2007101 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Control group)
Number of subjects: 45
Study 2007101 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia (ICNB)
Number of subjects: 45
Study 7187082 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the logistic function probabilities provided to emergency room physicians (401 patients with probabilities)
Number of subjects: 643
Study 7187082 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic modalities without logistic function probabilities (455 patients without probabilities)
Number of subjects: 643
Study 31577671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR) with 50% reduction of CNI
Number of subjects: 525
Study 31577671 — intervention group
Group type: COMPARATOR
Intervention: Standard CNI-based immunosuppression
Number of subjects: 525
Study 31577671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR) with early CNI minimization
Number of subjects: 525
Study 31286118 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine air polishing (G)
Number of subjects: 30
Study 31286118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate air polishing (B)
Number of subjects: 30
Study 31286118 — intervention group
Group type: COMPARATOR
Intervention: Manual scaling with carbon-fiber curette (C)
Number of subjects: 30
Study 28500784 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐PDT (Daylight Photodynamic Therapy)
Number of subjects: 28
Study 28500784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional laser‐assisted DL‐PDT
Number of subjects: 28
Study 27466241 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet providing information to fathers during their partners' pregnancies
Number of subjects: 554
Study 27466241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 554
Study 25123092 — intervention group
Group type: EXPERIMENTAL
Intervention: PACU
Number of subjects: 200
Study 25123092 — intervention group
Group type: COMPARATOR
Intervention: ICU
Number of subjects: 200
Study 21075536 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine-Gel®
Number of subjects: 30
Study 21075536 — intervention group
Group type: COMPARATOR
Intervention: Flammazine®
Number of subjects: 30
Study 19776406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (90 mg/m²) plus cytarabine (100 mg/m²)
Number of subjects: 657
Study 19776406 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose daunorubicin (45 mg/m²) plus cytarabine (100 mg/m²)
Number of subjects: 657
Study 17598694 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation of topiramate (25 mg)
Number of subjects: 24
Study 17598694 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of topiramate (25 mg)
Number of subjects: 24
Study 17598694 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated AUCs
Number of subjects: 24
Study 15380493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing practice guidelines to primary care physicians after patient discharge
Number of subjects: 832
Study 11303823 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (OD) gentamicin dosing
Number of subjects: 179
Study 11303823 — intervention group
Group type: COMPARATOR
Intervention: Three times daily (TD) gentamicin dosing
Number of subjects: 179
Study 9600579 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg oral m-CPP
Number of subjects: 12
Study 9600579 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oral m-CPP
Number of subjects: 12
Study 9600579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9600579 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg oral m-CPP (females only)
Number of subjects: 12
Study 7992274 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with Elmedistraal
Number of subjects: 12
Study 7992274 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study 3290005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 65
Study 3290005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30292454 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training group assisted by an integrated video recording system during training (Group B)
Number of subjects: 50
Study 30292454 — intervention group
Group type: COMPARATOR
Intervention: Natural self-training group without a trainer (Group A)
Number of subjects: 50
Study 28301205 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor Platelet-Rich Plasma (Lp-PRP)
Number of subjects: 24
Study 28301205 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte-Rich Platelet-Rich Plasma (Lr-PRP)
Number of subjects: 24
Study 28301205 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study 25573406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium+olodaterol FDC 2.5/5 μg
Number of subjects: 5162
Study 25573406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium+olodaterol FDC 5/5 μg
Number of subjects: 5162
Study 25573406 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 2.5 μg
Number of subjects: 5162
Study 25573406 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 5 μg
Number of subjects: 5162
Study 25573406 — intervention group
Group type: COMPARATOR
Intervention: Olodaterol 5 μg
Number of subjects: 5162
Study 23618609 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EP group) with bupivacaine
Number of subjects: 132
Study 23618609 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous morphine (SC group) with fentanyl
Number of subjects: 132
Study 23618609 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EP group)
Number of subjects: 132
Study 23618609 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous morphine (SC group)
Number of subjects: 132
Study 21471821 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR; containing ∼ 6.2 mmol of nitrate)
Number of subjects: 9
Study 21471821 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (placebo, PL; containing ∼ 0.0047 mmol of nitrate)
Number of subjects: 9
Study 18299546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (telephone-based education for patients and guidelines for physicians)
Number of subjects: 272
Study 18299546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 272
Study 17219967 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of Triptorelin (3.75 mg) at 6-week intervals
Number of subjects: 46
Study 17219967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of Triptorelin (3.75 mg) at 4-week intervals
Number of subjects: 46
Study 17219967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimes (SC and IM)
Number of subjects: 46
Study 12953165 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 55
Study 10793603 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat 0.02 mg kg‐1 (group A)
Number of subjects: 30
Study 10793603 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat 0.04 mg kg‐1 (group B)
Number of subjects: 30
Study 10793603 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (group C)
Number of subjects: 30
Study 8805989 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PEMF coils
Number of subjects: 13
Study 8805989 — intervention group
Group type: COMPARATOR
Intervention: Inactive PEMF coils
Number of subjects: 13
Study 1282428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual marker analysis flow‐cytometry using CD5 and CD19 markers
Number of subjects: 23
Study 1282428 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR analysis of the configuration of the Ig heavy chain gene region
Number of subjects: 23
Study 6691878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 61
Study 6691878 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 61
Study 31680610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory Surgery Center (ASC)
Number of subjects: 50
Study 31680610 — intervention group
Group type: COMPARATOR
Intervention: Arthroplasty Ward
Number of subjects: 50
Study 31680610 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC for TKA
Number of subjects: 50
Study 31680610 — intervention group
Group type: COMPARATOR
Intervention: Arthroplasty Ward for TKA
Number of subjects: 50
Study 31680610 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC for THA
Number of subjects: 50
Study 30642076 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α inhibitors (TNFi)
Number of subjects: 50
Study 30642076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30373740 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (2000-mg doses 8 times over 4 days)
Number of subjects: 606
Study 30373740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 30373740 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 606
Study 27829388 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Oral Screening (MOS) tool
Number of subjects: 211
Study 27829388 — intervention group
Group type: COMPARATOR
Intervention: Oral Health Impact Profile (OHIP-14)
Number of subjects: 211
Study 27829388 — intervention group
Group type: COMPARATOR
Intervention: Dental assessment by trained study dentists
Number of subjects: 211
Study 24797294 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial treatment (40 mg/kg of amoxicillin‐clavulanate per day for 7 days)
Number of subjects: 84
Study 24797294 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial treatment
Number of subjects: 84
Study 24797294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 22039291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) containing 0.5 mg NE and 0.035 mg EE
Number of subjects: 24
Study 22039291 — intervention group
Group type: EXPERIMENTAL
Intervention: OC plus telaprevir (750 mg every 8 hours)
Number of subjects: 24
Study 20561115 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme (ITOHEP)
Number of subjects: 113
Study 20561115 — intervention group
Group type: COMPARATOR
Intervention: Standard oral hygiene education (ST)
Number of subjects: 113
Study 17173280 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 40
Study 17173280 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 40
Study 15887056 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 9
Study 15887056 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid drink (control)
Number of subjects: 9
Study 12040477 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg rhGM-CSF solution (group A, n = 18)
Number of subjects: 41
Study 12040477 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (group B, n = 23)
Number of subjects: 41
Study 9822000 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 60
Study 9822000 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 60
Study 9822000 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetics
Number of subjects: 60
Study 7853451 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal aerobic exercise (12 min at 63% VO2 max)
Number of subjects: 60
Study 7853451 — intervention group
Group type: COMPARATOR
Intervention: Control group (completed two short unrelated questionnaires for 12 min)
Number of subjects: 60
Study 2548554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 0.5 mg
Number of subjects: 10
Study 2548554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1 mg
Number of subjects: 10
Study 2548554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 0.5 mg daily (multiple dose phase)
Number of subjects: 10
Study 2548554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1 mg daily (multiple dose phase)
Number of subjects: 10
Study 73949 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (coronary bypass surgery)
Number of subjects: 0
Study 73949 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study 31228593 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) of antagonist muscles plus single ES session on injected muscles
Number of subjects: 30
Study 31228593 — intervention group
Group type: COMPARATOR
Intervention: Single ES session on injected muscles alone
Number of subjects: 30
Study 28094601 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator program (PAtient COach)
Number of subjects: 24
Study 22538279 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-alternating vibration (SV)
Number of subjects: 18
Study 22538279 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency (5-10-15-20-25-30 Hz)
Number of subjects: 18
Study 22538279 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion angle (60°)
Number of subjects: 18
Study 22538279 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot stance condition
Number of subjects: 18
Study 22538279 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional load (equal to one-third of body weight)
Number of subjects: 18
Study 21787159 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic high-flux dialyzer, polyethersulfone membrane
Number of subjects: 60
Study 21787159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose triacetate (CTA) high-flux membrane
Number of subjects: 60
Study 21787159 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic low-flux dialyzer, polymethylmethacrylate (PMMA) membrane
Number of subjects: 60
Study 19549125 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based prostate-specific antigen (PSA) testing
Number of subjects: 2022
Study 19549125 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based PSA testing
Number of subjects: 2022
Study 16960930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg once daily
Number of subjects: 204
Study 16960930 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine 50 mg three times daily
Number of subjects: 204